Therefore, it is proposed that screening for cblC deficiency be considered in patients presenting with either ambiguous intravascular hemolysis, hematuria, and proteinuria, or renal thrombotic microangiopathy (TMA) [5, 6]. The gene discussed is CBLC; the disease is hemolysis.